Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab for Active Rotator Cuff Tendinopathy
2022-502068-19-00Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in shoulder tendinopathy comparing Secukinumab with Placebo (2 arms). Primary endpoint: Change from Baseline in WORC Physical Symptom Domain score at Week 16. Started Aug 2023; status: completed.
02
Drugs
secukinumab
03
Conditions
shoulder tendinopathy
Beyond the preview
Go deeper on 2022-502068-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502068-19-00.